Medy-Tox Inc. (KOSDAQ:086900)

South Korea flag South Korea · Delayed Price · Currency is KRW
126,400
-5,500 (-4.17%)
At close: Feb 6, 2026
7.85%
Market Cap887.30B +6.7%
Revenue (ttm)241.80B +0.1%
Net Income21.84B +95.0%
EPS3,398.79 +111.2%
Shares Out7.02M
PE Ratio37.19
Forward PE37.08
Dividend1,200.00 (0.95%)
Ex-Dividend DateSep 29, 2025
Volume44,420
Average Volume69,292
Open129,000
Previous Close131,900
Day's Range123,500 - 129,900
52-Week Range114,700 - 182,700
Beta0.36
RSI50.04
Earnings DateMar 20, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 718
Stock Exchange KOSDAQ
Ticker Symbol 086900
Full Company Profile

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.

Financial Statements